- Home
- DAWN
as 11-26-2025 3:40pm EST
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 624.8M | IPO Year: | 2021 |
| Target Price: | $26.56 | AVG Volume (30 days): | 3.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.63 - $14.46 | Next Earning Date: | 11-04-2025 |
| Revenue: | $133,672,000 | Revenue Growth: | 31.11% |
| Revenue Growth (this year): | 12.88% | Revenue Growth (next year): | 48.27% |
Stock Insider Trading Activity of Day One Biopharmaceuticals Inc. (DAWN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dubow Adam | DAWN | Gen Counsel & Secretary | Nov 17 '25 | Sell | $8.91 | 4,319 | $38,502.59 | 62,626 | |
| Bender Jeremy | DAWN | CHIEF EXECUTIVE OFFICER | Nov 17 '25 | Sell | $8.91 | 15,894 | $141,690.24 | 177,165 | |
| Merendino Lauren | DAWN | Chief Commercial Officer | Nov 17 '25 | Sell | $8.91 | 3,726 | $33,216.17 | 50,809 | |
| York Charles N II | DAWN | COO and CFO | Nov 17 '25 | Sell | $8.91 | 4,062 | $36,211.51 | 294,715 |
Latest Day One Biopharmaceuticals Inc. News
DAWN Breaking Stock News: Dive into DAWN Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
How Recent Developments Are Shaping the Day One Biopharma Investment Story
GlobeNewswire
3 days ago
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
GlobeNewswire
17 days ago
Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
Simply Wall St.
21 days ago
Day One Biopharmaceuticals (DAWN): Revenue Forecast to Grow 30.6% Annually, Reinforcing Bull Case
GuruFocus.com
23 days ago
Day One Biopharmaceuticals Inc (DAWN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ...
Zacks
23 days ago
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
23 days ago
Day One Reports Third Quarter 2025 Financial Results and Corporate Progress
GuruFocus.com
24 days ago
Day One Biopharmaceuticals Inc (DAWN) Q3 2025 Earnings Report Preview: What To Expect
Compare DAWN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DAWN Day One Biopharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.